Mark De Boer

Title: Mark De Boer: Innovator in Monoclonal Antibody Research

Introduction

Mark De Boer is a notable inventor based in Beverwyk, Netherlands. He has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies. With a total of eight patents to his name, De Boer has focused on innovative methods for preventing and treating antibody-mediated diseases.

Latest Patents

One of De Boer's latest patents involves anti-CD40 antibodies capable of blocking B-cell activation. The methods presented in this patent include the administration of a monoclonal antibody that binds to the human CD40 antigen located on the surface of B cells. This binding action prevents the growth or differentiation of the B cells, offering a potential therapeutic approach for various diseases. The patent also discusses monoclonal antibodies useful in these methods and the epitopes that are immunoreactive with such antibodies.

Career Highlights

Throughout his career, Mark De Boer has worked with prominent companies in the biotechnology sector. He has been associated with Chiron Corporation and Novartis Vaccines & Diagnostics GmbH, where he contributed to groundbreaking research and development projects. His work has had a lasting impact on the field of immunology and therapeutic interventions.

Collaborations

De Boer has collaborated with various professionals in his field, including Leah B. Conroy. These partnerships have facilitated the advancement of research and the successful development of innovative solutions in antibody therapy.

Conclusion

Mark De Boer stands out as a significant figure in the realm of monoclonal antibody research. His innovative patents and collaborations have paved the way for advancements in treating antibody-mediated diseases. His contributions continue to influence the field and inspire future research endeavors.